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Abstract 
Shakya, Astha. M.S. Department of Biochemistry and Molecular Biology, Wright 
State University, 2019. ERK3 negatively regulates the IL-6/STAT3 signaling via 
SOCS3  
Mitogen activated protein kinases (MAPKs) are Ser/Thr kinases that relay the extracellular 
signal into intracellular responses and regulate several biological responses. They are 
classified into conventional MAPKs and atypical MAPKs. Extracellular signal regulated 
kinase 3 (ERK3) is an atypical MAPK that has a single phospho-acceptor site (Ser 189) in 
its activation motif instead of the canonical Thr-Xaa-Tyr (TXY) motif of conventional 
MAPK like ERK1/2. ERK3 comprises of a unique C terminal tail and a central C34 domain 
that further distinguishes it from ERK1/2. Moreover, compared to ERK1/2, much less is 
known about the upstream activators and the downstream targets of ERK3. Here, our study 
identifies IL-6 signaling to be negatively regulated by ERK3. We show that ERK3 
downregulates the IL-6 target genes and STAT3 phosphorylation. IL-6 is a multifunctional 
pleiotropic cytokine that signals predominantly via JAK/STAT signaling pathway. In 
response to IL-6, STAT3 is phosphorylated at Tyrosine 705 (Y705) residue by JAK2, 
which successively activates STAT3 as a transcription factor. The IL-6/STAT3 pathway is 
negatively regulated by a feedback inhibitor SOCS3 (Suppressor of Cytokine Signaling 3) 
which binds to JAK2, hence, preventing the phosphorylation and activation of STAT3. 
Interestingly, this study reveals that ERK3 interacts with SOCS3 via its C34 domain. Until 
now, there has been no information about the physiological or the biochemical function of 
the C34 domain of ERK3. Hence this study has identified a novel role of ERK3’s C34 
domain. Furthermore, we show that ERK3 facilitates the interaction between SOCS3 and 
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JAK2, promoting the inhibition of STAT3 Y705 phosphorylation and activation. Taken 
together, the findings of our study provide important and novel insights into the negative 
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I. Introduction 
A. Mitogen Activated Protein Kinases (MAPKs) 
Mitogen activated protein kinases (MAPKs) are serine-threonine kinases that belong to a 
well-conserved and large family of proline directed serine/threonine kinases called CMGC. 
The CMGC includes four major groups of kinases namely: Cyclin-dependent kinases, 
MAPKs, Glycogen synthase kinases and Casein kinases (Manning et al. 2002). MAPKs 
are activated by a variety of extracellular stimuli and play integral roles in regulating 
diverse cellular events such as cell proliferation, differentiation, apoptosis, metabolism and 
motility. Based on the phosphorylation consensus, sequence identity, signaling profile and 
function, six different MAPKs have been identified: ERK1/2, ERK3/4, ERK5, ERK7/8, 
JNK1/2/3 and p-38 isoforms α/β/γ(ERK6)/δ. (Dhillon et al. 2007; Krens, Spaink, and 
Snaar-Jagalska 2006; Yoon and Seger 2006; Inbal Wortzel and Rony Seger 2011) 
 
Classically, MAPK pathway is organized into a three-tier kinase module comprising of a 
MAP kinase kinase kinase (MAPKKK), a MAP kinase kinase (MAPKK) and the effector 
MAP kinase itself. However, this does not stand true for all MAPKs. Hence based on their 
ability to get phosphorylated and activated by MAPKK family members, Coulombe and 
Meloche classified the MAPKs into conventional/classical MAPKs and atypical MAPKs 
(Fig 1). The conventional MAPKs includes four MAPKs: ERK1/2, JNK1/2/3, p38s and 
ERK5. These have a dual phospho acceptor motif consisting of threonine and tyrosine 
(TXY) in their kinase domain. On the other hand, the atypical MAPKs consists of ERK3, 
ERK4 and Nemo-like kinase (NLK) which have only a single phospho acceptor site in their 
activation loop. Besides these, ERK7, another MAPK with a TEY motif, is also considered 
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an atypical MAPK as it is catalyzed by the MAPK itself rather than an upstream MAPKK 
(Coulombe and Meloche 2007; Kostenko, Dumitriu, and Moens 2012). Compared to the 
widely studied classical MAPKs, much less is known about the regulatory mechanism and 
physiological functions of the unconventional MAPKs. 
 
 
Figure 1: Schematic representation of human MAPKs structure 
All MAPKs consist of a central kinase domain (shown in blue) with phospho acceptor 
site(s) in the activation motif (TXY or SEG), flanked by N- and C-terminal extensions of 
variable lengths. Some MAPKs also have unique domains, such as transactivation domain 
(TAD), nuclear localization sequence (NLS), C34 (conserved region in ERK3/4), AHQr, 
alanine (A), histidine (H) and glutamine (Q) rich domain. Numbers in the kinase domains 
indicate the percentage of homology of the kinase domain to that of ERK1.  (Coulombe 
and Meloche 2007) 
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B. Extracellular signal Regulated Kinase 3 (ERK3) 
Extracellular signal regulated kinase 3 (ERK3) is an atypical MAP kinase. It is also known 
as MAPK6 and was first cloned in rats in the early 90s using an ERK1 derived probe, 
followed by subsequent cloning of mouse and human ERK3. It bears approximately 50% 
homology with ERK1 within the catalytic domain (Boulton et al. 1991; Andrew X. Zhu, 
Yi Zhao, David E. Moller 1994; Meloche, Beatty, and Pellerin 1996). However, instead of 
the Thr-Glu-Tyr (TEY) motif of the ERK1/2, ERK3 has a single phospho acceptor site in 
its activation motif as Ser-Glu-Gly (SEG). Moreover, the phosphorylation at the Ser 189 is 
not affected by the common cellular stimuli, cellular stress or mitogenic factors of 
conventional MAPKs (Cheng et al. 1996). Instead, ERK3 has been shown to be 
phosphorylated in trans by an upstream kinase like the group I p21- activated kinases 
(PAKs) and in cis by autophosphorylation in order to activate itself (Déléris et al. 2011; 
Coulombe and Meloche 2007; De La Mota-Peynado, Chernoff, and Beeser 2011; 
Elkhadragy et al. 2018).  
Although, ERK3 shares about 50% similarity with the extensively studied ERK1/2, only a 
few substrates of ERK3 have been discovered yet, compared to the exhaustive list of 
ERK1/2 substrates. This could be attributed to the SEG motif, C34 domain and the unique 
C terminus of ERK3 (Cheng et al. 1996; Coulombe and Meloche 2007; Sergiy Kostenko 
2012). MAPK- activated protein kinase 5 (MK5) (Seternes et al. 2004; Schumacher et al. 
2004), Steroid Receptor Coactivator 3 (SRC3) (Long et al. 2012) and tyrosyl-DNA 
phosphodiesterase 2 (TDP2) (Bian et al. 2016) are the few well-studied ERK3 substrates. 
However, there are some conflicting reports regarding how ERK3 and MK5 affect each 
other, nonetheless, their physical association and their role in each other’s 
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phosphorylation/activation are certain (Seternes et al. 2004; Schumacher et al. 2004; 
Kostenko, Dumitriu, and Moens 2012). ERK3 also interacts and phosphorylates SRC3, a 
bona fide oncogene, at S857 leading to cancer progression (Long et al. 2012). Furthermore, 
ERK3 phosphorylates TDP2, a DNA repair enzyme, at S60 to regulate its 
phosphodiesterase activity, DNA damage response and chemoresistance to Top2 inhibitors 
(Bian et al. 2016). Meanwhile, a few proteins which regulate ERK3 at gene and/or protein 
level have also been discovered, which includes BRAF (Hoeflich et al. 2006; Chen et al. 
2019), BMI1 (Elkhadragy et al. 2017) and DUSP2 ( Perander et al. 2017). 
Unlike most other MAPKs which are expressed in all eukaryotes, ERK3 is unique  to 
vertebrates (Krens, Spaink, and Snaar-Jagalska 2006; Kostenko, Dumitriu, and Moens 
2012). It is expressed ubiquitously in all tissues at varying levels with the highest 
expression of the mRNA in the brain, skeletal muscle and gastrointestinal tract. Also, 
interestingly, there is an increased expression of the Erk3 mRNA during embryogenesis 
(Turgeon, Saba-El-Leil, and Meloche 2000).  
The human ERK3 protein has a molecular mass of 100 kDa and comprises 721 amino 
acids. Its general structure consists of a N-terminal kinase domain, followed by a C34 
domain in the center and a long, distinctive C-terminus tail (Fig 1). The C34 domain is 
conserved in the ERK3 and ERK4, however, its biochemical and cellular functions are yet 
to be identified. The C terminus tail is distinctive to ERK3 and is highly phosphorylated 
during mitosis leading to an increased protein stability (Turgeon, Saba-El-Leil, And 
Meloche 2000; Coulombe And Meloche 2007).  
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ERK3 has been reported to be localized in both the nuclear and cytoplasmic compartments 
of the cell (Cheng, Boulton, and Cobb 1996; Manning et al. 2002; Déléris et al. 2011; 
Elkhadragy et al. 2018). The localization of ERK3 is unaffected by any mitogenic or stress 
stimuli. However, a study by Julien et al., 2003 was successful in showing that the 
cytoplasmic localization of ERK3 is dependent on CRM1 (Chromosomal maintenance 1).  
C. ERK3 in cancer 
ERK3 is dysregulated in several cancers. It has differential role in cancer, based on the 
tissue type. A study performed by Long and colleagues demonstrated that ERK3 increases 
the lung cancer cell migration and invasion through phosphorylation of a bona-fide 
oncogene SRC3 (Steroid receptor co-activator 3). Another study by Al-Mahdi et al., 
showed that ERK3 mediates morphological changes in breast cancer cells and further 
promotes the cancer cell migration (Al-Mahdi et al. 2015).  Besides these, upregulation of 
ERK3 expression has been reported in oral cancer (Rai, Mahale, and Saranath 2004), lung 
cancer (Long et al. 2012), head and neck cancer (Elkhadragy et al. 2017), breast cancer 
(Al-Mahdi et al. 2015) and gastric cancer (Liang et al. 2005). 
 
On the contrary, several studies have also suggested that ERK3 has inhibitory roles on 
the growth, migration and invasion of cancer cells. In melanoma cells where ERK3 is 
upregulated and stabilized by BRAF, ERK3 functions as a suppressor of cancer cell 
migration, invasion and proliferation. Moreover, lower expression of ERK3 corresponded 
with poor prognosis in melanoma patients (Hoeflich et al. 2006; Chen et al. 2019). 
Similarly, ERK3 decreases cell proliferation of hepatocarcinoma cell line (Xiang, Wang, 
and Xiang 2014). Taken together, these findings suggest that ERK3 plays a differential role 
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in different cancers, based on the tissue type. Besides this, ERK3 is  involved in 
chemoresistance of cancer cells as it is highly upregulated in chemo-resistant cells (Bian 
et al. 2016). A few mutations of ERK3 have also been reported in lung, ovary and skin 
cancer (Greenman et al. 2007; Ding et al. 2008; Kostenko, Dumitriu, and Moens 2012). 
These mutations include R64C, L290V, L290P and G234C in the kinase domain, as well 
as K489T and E508K in the C34 domain of ERK3. Among these, L290 mutation is fairly 
studied. Compared to wild type ERK3, L290P/V mutants have increased cytoplasmic 
localization, and ability in promoting migration and invasion in different cancer cells 
(Alsaran et al. 2017).  
 
D. Interleukin-6 (IL-6) 
In 1986, Hirano et al. identified a B cell differentiation factor from antigen-stimulated 
peripheral blood mononuclear cells which induced B cells to produce antibodies, hence 
named as B-cell stimulatory factor-2 (BSF-2) (Yoshizaki et al. 1982; Hirano et al. 1986) 
Simultaneously different groups independently cloned proteins IFN-ß2 (Gauldie et al. 
1987; Andus et al. 1987), hybridoma/plasmacytoma growth factor (Nordan, Pumphrey, and 
Rudikoff 1987) and hepatocyte-stimulating factor (Uyttenhove, Coulie, and Van Snick 
1988; Snick et al. 1988)  which were later proven to be the same molecule as BSF-2, that 
is now popularly known as Interleukin-6 (Uyttenhove, Coulie, and Van Snick 1988; Andus 
et al. 1987; Naka, Nishimoto, and Kishimoto 2002). IL-6 is a 26 kDa glycoprotein with 
four alpha helical structures, and is produced by B cells, T cells, macrophages, monocytes, 
keratinocytes, fibroblasts, adipocytes, mesangial cells, endothelial cells and several tumor 
cells (Andus et al. 1987; Hirano et al. 1986;  Babon, Varghese, and Nicola 2014a; 
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Yoshizaki et al. 1982; Hunter and Jones 2015). It is a multifunctional pleiotropic cytokine 
with a wide range of biological functions, including but not limited to immune regulation, 
organ development, metabolism, hematopoiesis, and oncogenesis (Hirano 1998; Babon, 
Varghese, and Nicola 2014). Due to its myriad of function, dysregulation of IL-6 has 
implication in several diseases and conditions like rheumatoid arthritis, diabetes, 
inflammatory bowel disease, Castleman’s disease, encephalomyelitis, systemic sclerosis 
and different types of cancer (Hirano et al. 1986; Tanaka, Narazaki, and Kishimoto 2014; 
Chonov et al. 2019). Although advances have been made in understanding the complex 
signaling pathways associated with this cytokine, little is known about the crosstalk 
between IL-6 signaling and atypical MAPKs. 
 
E. IL-6 signaling 
IL-6 along with ten other structurally similar cytokines like leukemia inhibitory factor 
(LIF), oncostatin m (OSM), ciliary neurotrophic factor (CNTF), and cardiotrophin-1 make 
up the family of IL-6 type cytokines. These cytokines signal via a cell surface trans-
membrane receptor comprising a dimer of a cytokine specific non-signaling alpha receptor 
and a common signal transducing component IL-6ST (Peter C Heinrich et al. 2003; Babon, 
Varghese, and Nicola 2014). IL-6ST, also known as GP130, is a ubiquitously expressed 
transmembrane protein, which lies at the nexus of IL-6 type cytokine signaling.  
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Figure 2: IL-6 transduces its signal primarily via the JAK STAT pathway.  
IL-6 first binds to the IL-6R which subsequently induces the dimerization of the signal 
transducing receptor IL-6 ST (gp130). Janus Kinase (JAK) which is bound to IL-6ST is 
then activated by auto phosphorylation, further phosphorylating five tyrosine residues in 
the IL6ST. Following this, STAT3 is recruited to the phosphorylated IL6ST through its 
SH2 domain and then is phosphorylated at Y705 by JAK. The phosphorylated STATs 
forms dimers and enter into the nucleus where they bind to the promoters of the targeted 
genes and activate gene transcription. Some of the IL-6/STAT3 targeted genes, such as 
SOCS3, are feedback inhibitors of IL-6 signaling. SOCS3 protein binds to JAK2 and 
IL6ST and negatively regulates IL-6/STAT3 pathway (P C Heinrich et al. 1998; Babon, 
Varghese, and Nicola 2014). 
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IL-6 can bind to two types of IL-6 alpha receptors (IL-6R): membrane bound IL-6R (mIL-
6R) and soluble IL-6R (sIL-6R). Based on type of the receptor, IL-6 signaling is 
differentiated into classical IL-6 signaling and trans IL-6 signaling respectively. Despite 
the differences in the receptors, association of IL-6 with IL-6R leads to the homo-
dimerization of IL-6ST (Figure 2, Murakami et al. 1993; Ullrich and Schlessinger 1990). 
Furthermore, IL-6ST does not have an intrinsic kinase domain and is covalently bound to 
the intracellular tyrosine kinase Janus Kinase (JAK). JAK1, JAK2 and TYK2 are the three 
JAKs that are bound to IL6ST among which JAK1 and JAK2 has the most prominent effect 
on IL-6 signaling (P C Heinrich et al. 1998; Stahl et al. 1994). Upon IL-6 stimulation, JAK 
gets activated via auto-phosphorylation of the tyrosine residue within its activation loop 
and simultaneously phosphorylates tyrosine residues on the cytoplasmic domain of IL6ST. 
This provides docking sites for molecules with a Src-homology-2 (SH2) domain, 
particularly members of the STAT family, STAT1 and STAT3 (Hemmann et al. 1996; 
Babon, Varghese, and Nicola 2014a; Peter C Heinrich et al. 2003). Subsequently, STATs 
get phosphorylated at tyrosine residue by JAK, form homodimer or heterodimer and 
translocate into the nucleus where they regulate transcription of target genes (Rodig et al. 
1998; Feng et al. 1997; Eulenfeld et al. 2012; Stahl et al. 1994).  
 
Signal Transducer and Activator of Transcription (STAT) family proteins are the latent 
cytoplasmic transcription factors that are key to cytokine signaling. Till date, 7 members 
of STAT family have been discovered and are designated as STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b and STAT6 (Ihle 1996; Niemand et al. 2003). These proteins 
have highly conserved structural motifs comprising of a tetramerization domain and a 
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leucine-zipper like domain at the N-terminus, a central DNA binding domain followed by 
a SH3 like domain, SH2 domain, and a transactivation domain at the C terminus. Besides 
these, all STATs have a tyrosine residue towards the C terminus which when 
phosphorylated, activates the protein by inducing dimerization of two STAT molecules (P 
C Heinrich et al. 1998; Ihle 1996). IL-6 potently activates STAT3 by inducing its 
phosphorylation at the tyr 705 (Y705) residue via JAK2 which is essential for STAT3’s 
transcriptional activities (Yokogami et al. 2000; Huang et al. 2014; P C Heinrich et al. 
1998). 
 
The IL-6 signaling pathway is highly regulated with respect to both magnitude and 
duration. Till date, three major negative regulators of IL-6 signaling have been discovered: 
tyrosine phosphatases, protein inhibitor of activated STAT-3 (PIAS3) and suppressor of 
cytokine signaling-3 (SOCS3) (P C Heinrich et al. 1998; Babon, Varghese, and Nicola 
2014). Although these inhibitors differ in structure and mechanism of action, their basic 
strategy for IL-6 inhibition involves the regulation of the Y705 phosphorylation of STAT3.   
 
F. Suppressor of Cytokine Signaling-3 (SOCS3) 
SOCS family of proteins were discovered in 1997 concurrently by three groups as a 
negative feedback inhibitor of cytokine signaling cascades (Naka et al. 1997; Starr et al. 
1997; Endo et al. 1997). These proteins inhibit the cytokines that initially induces its 
expressions and are hence also known as SSIs (STAT induced STAT inhibitors) and CISs 
(Cytokine inducible SH2 proteins). There are eight members in this family (CIS and 
SOCS1–SOCS7) and are distinguished by the central SH2 domain and a C-terminal SOCS 
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box (Fig 3). These conserved domains allow all SOCS proteins to inhibit the cytokine 
signaling by two distinct mechanisms. The central SH2 domain binds to the SH2 docking 
site of cell surface receptors like IL6ST, preventing the recruitment of STAT proteins 
(Lang et al. 2003) while the SOCS box promotes the ubiquitination of target proteins by 
interaction with elongins B/C and Cullin 5 (Babon et al. 2008). In addition to these 
domains, SOCS1 and SOCS3 comprises of a kinase inhibitory region (KIR) which enables 
them to directly bind to and inhibit JAK’s enzymatic activity, thereby suppressing the 
activation of tyrosine phosphorylation of STAT and the transcription of IL-6 target genes. 
(Helman et al. 1998; Peter C Heinrich et al. 2003; Inagaki-Ohara et al. 2013; Babon, 
Varghese, and Nicola 2014). Hence SOCS1 and SOCS3 are considered to be the most 
potent inhibitors of cytokine signaling. 
 
Figure 3: Schematic illustration of structure of SOCS proteins.  
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The SOCS family comprises eight members all of which share a central SH2 domain, an 
extended SH2 domain (ESS) and a C-terminal SOCS box. SOCS1 and SOCS3 additionally 
harbor the kinase inhibitory region (KIR) domain that serves as a pseudo-substrate for 
JAKs. SOCS1 also contains a nuclear localization signal (NLS) (Inagaki-Ohara et al. 
2013). 
 
However, in vivo studies with conditional knock out mice demonstrated that SOCS3 has 
more profound effect on IL-6 signaling compared to SOCS1 (Roberts et al. 2001; 
Alexander et al. 1999; Babon, Varghese, and Nicola 2014a). Therefore, SOCS3 is 
considered to be the primary regulator of the IL-6 signaling. SOCS3 binds to the JH1 
domain of JAK2 via its KIR domain which further prevents the phosphorylation and 
activation of STAT3 (Kershaw et al. 2013; Y. Wang et al. 2013). Studies have also reported 
that SOCS3 is highly specific in inhibiting STAT3 activated by IL-6 type cytokines 








` 13  
G. Hypothesis and Specific Aims 
ERK3 is an atypical MAP kinase that shares about 50% homology with the regular MAP 
kinase ERK1/2, within the catalytic domain. However, unlike ERK1/2 that has a conserved 
Thr-Xaa-Tyr (TXY) as a phospho acceptor motif, ERK3 has a single phospho acceptor site 
in Ser-Glu-Gly (SEG). Moreover, a long C-terminus tail also distinguishes ERK3 from its 
other MAP kinase counterparts. While these features make ERK3 unique, they also stand 
as challenges in understanding the biochemical and physiological roles of ERK3. 
Interestingly, a gene microarray analysis (Fig 4; performed in collaboration with Dr. 
Michael Markey) showed that with the knockdown of ERK3, there is an increase in the 
expression of several IL-6 target genes in A549 lung cancer cell line and A375 melanoma 
cell line, suggesting that ERK3 negatively regulates the IL-6 signaling. In addition, a Yeast 
two hybrid (Y2H) screening (Vinayagam et al. 2011) identified SOCS3 as an interacting 
partner of ERK3 protein. As mentioned above, SOCS3 is a negative feedback regulator of 
IL-6 signaling pathway. Based on these interesting preliminary information, we 
hypothesized that ERK3 negatively affects the IL-6 signaling pathway via SOCS3. To 
test the hypothesis, we propose two specific aims: 1) To identify the role of ERK3 in IL-
6 signaling, 2) To study the interaction between ERK3 and SOCS3 and its implication 
in regulating IL-6 signaling. 
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Figure 4: ERK3 negatively regulates the expression of IL-6 target genes 
A549 lung cancer cells and A375 melanoma cells were transfected with 30nm of either 
non-targeting control siRNA (siControl) or siRNA against ERK3 (siERK3). 
Subsequently, microarray gene analysis was done to elucidate the genes and pathways 
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II. Materials and Methods  
 
A. Cell culture and reagents: 
The human melanoma cell line A375 was obtained from Dr. Mitsiade’s Lab, Baylor 
College of Medicine (Mitisiades et al., 2011). Non-small cell lung cancer A549, cervical 
cancer HeLa as well as HEK293T were obtained from American Type Culture Collection 
(ATCC). A375, HeLa and HEK293T were cultured in Dulbecco’s Modified Eagle’s 
medium (DMEM) while A549 was cultured in Rosewell Park Memorial Institute medium 
(RPMI). Both the media were supplemented with 10% fetal bovine serum (FBS) and 1% 
antibiotics Penicillin-Streptomycin (pen-strep). IL-6 was purchased from Peprotech (#200-
06) and was used at 20-40 ng/ml for indicated times. The cells were serum starved for 24 
hours prior to the treatment with IL-6. 0.1% BSA was used as vehicle control. 
 
B. Generation of stable cells: 
A375 stable cells were generated by lentiviral transduction of a short hairpin RNA 
(shRNA) to target ERK3 mRNA for stable knockdown of endogenous ERK3 (shERK3) in 
the presence of polybrene (5μg/mL). Similarly, a non-targeting shRNA (shGIPZ) was used 
to generate the control cell line. The cells were selected by puromycin (1 ug/ml) for 10 
days. The knockdown was confirmed by Western blotting analysis and RT-qPCR. 
 
C. Transient transfection of cells: 
siRNA transfection was conducted using DharmaFECT transfection reagent (Dharmacon, 
Lafayette, CO, USA) following the manufacturer’s instructions. Transfection with 
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plasmids were performed by FuGENE 6/HD transfection reagent (Active motif, USA) or 
Lipofectamine 3000 Reagent (Invitrogen/Thermofisher Scientific, Carlsbad, CA, USA). 
 
D. Western blotting assay: 
The cells were briefly washed with cold PBS, followed by lysis with EBC lysis buffer 
[50mM Tris (pH 7.5), 150 mM NaCl, 0.5% NP-40, 1mM Complete protease inhibitors 
(Roche Diagnostics) and 1mM phosphatase inhibitor cocktail III (Sigma Aldrich)]. The 
proteins lysates were mixed with 5X Laemmli sample buffer, boiled for 5 minutes at 90oC, 
then SDS-PAGE electrophoresis was done in 10% gel to separate the proteins, followed by 
Western blotting to transfer the proteins into nitrocellulose membranes. The membranes 
were subsequently blocked in 5% non-fat milk in phosphate-buffered saline with tween 20 
(PBS-T) for 30 minutes. Afterwards, the membranes were incubated overnight at 4oC or 
for 1 hour at room temperature with the primary antibodies, followed by 1-hour incubation 
with the appropriate secondary antibodies (HRP-conjugated goat anti- mouse [170-6516, 
Biorad] or anti-rabbit [170-6515, Biorad]) at room temperature. The Western blot was 
visualized by chemiluminescence (ThermoFisher). Following primary antibodies were 
used: anti-ERK3 (ab53277, 1:1000, Abcam), anti STAT3(9145, 1:1000, Cell Signaling), 
anti-phosphoSTAT3(Y705)(9139, 1:1000, Cell Signaling), anti-SOCS3 (sc-51699, 1:200, 
Santa Cruz), anti-JAK2 (3230, 1:1000, Cell Signaling), anti-Flag (F1804, 1:10000, Sigma 
Aldrich), anti-HA (1:1000, Sigma Aldrich) .  β-actin (A5316, 1:10000, Sigma Aldrich) was 
used as a loading control in the Western blotting experiments. 
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E. RNA extraction and RTqPCR 
Total RNA was extracted from cells using Trizol reagent (Ambion). Subsequently, reverse 
transcription (RT) was performed using SuperScript VILO Mastermix (Invitogen) on 
SimpliAmpTM Thermal Cycler (Applied Biosystems) based on the manufacturer’s 
protocol. The Real time Quantitative polymerase chain reaction (RT-qPCR) was later 
performed using TaqMan Universal Master Mix (Applied Biosystems), specific Roche 
Universal primers and Universal Probe (Roche Diagnostics) on the 7900HT Fast Real-
Time PCR Systems (Applied Biosystems) with GAPDH as the internal control. The 
relative expression to the normalizer sample was calculated using the ΔΔCT method. 
 
F. Two chamber transwell migration assay 
A modified two chamber transwell system (8.0 μm pore, BD Biosciences Falcon) was used 
to analyze the cell migration according to the manufacturer’s protocol. The Trypsin/EDTA 
detached cells were suspended in serum free medium with 20ng/ml of IL-6 (Peprotech) or 
Vehicle control (0.1% BSA). 0.2 ml of the cell suspension was added to the cell insert 
while a complete media with 10% FBS was added the lower chamber. The cells were 
allowed to migrate for 10 hours in a 37°C cell incubator. Later, the cells in the upper surface 
of the transwell were removed using cotton swabs, while the migrated cells on the lower 
surface were fixed with 4% paraformaldehyde for 15 min, followed by staining with 0.5% 
crystal violet solution for 10 mins. The migrated cells were then photographed and counted 
under a microscope at 50X magnification. 
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G. Co-immunoprecipitation 
The cells were transfected with respective plasmids. Two days post transfection, the cells 
were lysed with the EBC lysis buffer as described above. The lysate was precleared for 1 
hour using Protein A Affinity gel beads (Sigma-Aldrich Cat#P6486), followed by 
incubation with respective antibodies, anti-HA affinity agarose beads (Sigma-Aldrich 
Cat#E6779) or anti-Flag affinity agarose beads for three hours. As a control, cell lysates 
were also incubated with specific IgG, based on the antibody used, for 1 hour. The beads 
were then washed 3 times (10 minutes per wash) with EBC lysis buffer, followed by SDS-
PAGE and Western blotting as described before. 2% of the amount of protein supernatant 
for immunoprecipitation was loaded as input control. 
 
H. Immunofluorescence 
A549 cells were transiently co-transfected with psG5-ERK3-HA and psG5-SOCS3-flag 
plasmids. Two days post transfection the cells were stained using primary mouse anti-flag 
(F1804, Sigma aldrich), rabbit anti-ERK3(A302-654A, Bethyl laboratories) overnight at 
4oC. Subsequently, fluorescein-conjugated goat-anti-mouse and goat-anti-rabbit were 
added as secondary antibody. The cell nucleus was labelled using DAPI (1μg/ml). Images 
were then captured using a fluorescence microscope. 
 
I. Statistics 
Data were analyzed and graphs were made using GraphPad Prism 8. Data are expressed as 
mean ± standard deviation (SD). Statistical significance was determined by a two-sided 
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Student’s t-test and one-way ANOVA test. The P-value of less than 0.05 was considered 
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III. Results 
A. ERK3 negatively regulates IL-6 target genes 
To determine the role of ERK3 signaling on global gene expression in cancer cells, a 
transcriptome-wide microarray analysis was performed in A549 lung cancer cells and 
A375 melanoma cells (in collaboration with Dr. Michael Markey). The cells were 
transfected with either a non-targeting siRNA or a siRNA specifically targeting ERK3. 
Interestingly, the expression of several IL-6 target genes was upregulated in the cells when 
ERK3 was silenced (Fig 4). Since IL-6 is a pleiotropic cytokine with diverse effects in 
different biological processes (Naka, Nishimoto, and Kishimoto 2002; Chonov et al. 2019), 
we were interested to investigate the role of ERK3 in IL-6 signaling pathway. In order to 
validate the microarray results, RT-qPCR was performed to analyze the transcript level 
change of IL-6 response genes IL6ST, IL10RB, STAT1 with the knockdown of ERK3 in 
A549 and A375 cells (Fig 5a). In line with the microarray data, the depletion of ERK3 
upregulated the expression of these gene transcripts in both cell lines. 
 
Furthermore, to verify that ERK3 is a negative regulator of IL-6-induced gene 
transcription, ERK3 was knocked down transiently in A549 cells and stably in A375 cells, 
followed by an 24-hour serum starvation and successive treatment with 20 ng/ml of IL-6 
or vehicle control for 1 hour (Fig 5b, 5c). In both cell lines, IL-6 treatment along with 
ERK3 silencing led to a significant increase in the IL-6 induced transcript levels of IL6ST, 
IL10RB, and SOCS3, whereas the vehicle treatment with ERK3 knockdown did not show 
much effect (p>0.05) on transcript levels of the genes. 
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a) 
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c)       A375                                                                                        
                          
    
Figure 5: IL-6 target genes are upregulated by ERK3 knockdown in A549 and A375 
cells.  
a) A549 lung cancer cells and A375 melanoma cells were transiently transfected using 30 
nm of either non-targeting control siRNA (siControl) or siRNA against ERK3 (siERK3).  
A Taqman based RTqPCR was performed to analyze the effect of ERK3 knockdown in 
transcript levels of ERK3, IL6ST, IL10RB and STAT1. b-c) RTqPCR analysis of the 
effects of ERK3 knockdown followed by serum starvation and subsequent IL-6 stimulation 
on the transcript levels of IL-6 target genes in A549 (b) and A375 (c). Here, A549 cells 
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siRNA against ERK3 (siERK3) while A375 cells were stably knocked down with either 
non-targeting shRNA(shGIPZ) or shRNA against ERK3 (shERK3). Following the 
transfection, the cells were serum starved for 24 hour and then treated with 20 ng/ml of IL-
6 or 0.1% BSA (vehicle) for 1 hour. Values in the bar graph represent mean ± SD of three 
experiments. Significant difference is indicated with asterisks or pound keys on the basis 
of the P values obtained in student’s T test (***P<0.001, **0.001<P<0.01, *0.01<P<0.05) 
* indicates comparison between vehicle treated conditions while # indicates the 
comparison between IL-6 treated conditions. 
 
B. ERK3 downregulates phosphorylation of STAT3 at Y705 residue 
Following the observation of the negative effect of ERK3 on IL-6 target gene transcription, 
we were interested to test whether ERK3 regulates the transcriptional activity of STAT3. 
Since phosphorylation at tyrosine 705 (Y705) of  STAT3 is vital for transcription of IL-6 
responsive genes (Ihle 1996; Darnell 1996), we studied the effect of ERK3 on Y705 
phosphorylation of STAT3. We silenced ERK3 transiently in A549 cell line, a day later, 
the cells were serum starved for 24 hours, followed by IL-6 treatment at different time 
points. As anticipated, IL-6 stimulated Y705 phosphorylation of STAT3 (Fig 6a). 
Importantly, ERK3 knockdown greatly enhanced IL-6 induced Y705 phosphorylation at 
30 min time point, at which STAT3 phosphorylation was shown to reach the peak (Y. 
Wang et al. 2013; McHale et al. 2018). Similar experiments were performed in A375 cells 
with stable ERK3 knockdown. Remarkably, stable depletion of ERK3 enhanced IL-6 
induced Y705 phosphorylation of STAT3 throughout the treatment (Fig 6b). Taken 
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together, these results suggest that ERK3 negatively regulates the IL-6 signaling by 
downregulating Y705 phosphorylation of STAT3.  




                   
Figure 6: ERK3 knockdown increases the phosphorylation of STAT3 at Y705  
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a) A549 lung cancer cells were transfected with 30 nm of either siControl or siERK3. A 
day post transfection, the cells were serum starved for 24 hours and consecutivley 
stimulated with 20 ng/ml IL-6 for 30 mins or 60 mins. Cells were then harvested, and 
Western blotting was performed. b) Similarly, A375 cells with stable knockdown of ERK3 
(shERK3) or control cells (shGIPZ) were serum starved for 24 hours and were then 
stimulated with 20 ng/ml of IL-6 or vehicle for different time points. Western blotting was 
performed to analyze the change in phosphorylation of STAT3 at Y705 residue. 
 
C. Depletion of ERK3 enhances the IL-6 mediated cancer cell migration in A375 
Next we wanted to investigate the physiological significance of this negative regulation of 
IL-6 signaling by ERK3 via studying the cancer cell migration in A375 melanoma cells. 
While IL-6 stimulates melanoma cells migration (Linnskog et al. 2014), a recent study 
from our lab showed that ERK3 inhibited the migration of melanoma cells (Chen et al. 
2019), implying that one mechanism by which ERK3 suppresses melanoma cell migration 
is through to the downregulation of IL-6 signaling. To answer this, we performed a 
transwell migration assay in A375 cells with stable knockdown of ERK3 (shERK3) and 
control cells (shGIPZ) with or without IL-6 stimulation. As reported, migration of A375 
cells was separately enhanced by IL-6 (shGIPZ veh vs shGIPZ IL-6, Fig 7b and 7c) and 
ERK3 knockdown (shGIPZ veh vs shERK3 veh, Fig 7b and 7c). Of note, ERK3 
knockdown led to further significant increase in the migration of cells treated with IL-6 
(shERK3 IL-6 vs shERK3 Veh), which is in agreement with the increase in IL-6 induced 
Y705 phosphorylation of STAT3 by ERK3 knockdown (Fig 6b).  
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Figure 7: Knockdown of ERK3 increases migration of A375 cells treated with IL-6  
a) Western blot analysis of ERK3 protein levels in A375 cells with stable ERK3 
knockdown cells. b) Transwell migration assay of serum starved A375 stable cells 
stimulated with 20 ng/ml of IL-6 or vehicle (Veh) for 10 hours. The quantitative migration 
ability under each condition is represented as migrated cells per field on the y-axis of the 
bar graph. Values represent mean ± S.D. Significant difference is indicated with asterisks 
on the basis of the P values obtained in student’s T test (**0.001<P<0.01, *0.01<P<0.05) 
c) Representative images of migrated A375 cells with crystal violet staining. 
 
D. ERK3 interacts and colocalizes with SOCS3 
SOCS3, an inhibitor of IL-6/STAT3 signaling, was identified as an interacting partner of 
ERK3 in a Yeast 2 Hybrid screening dataset (Vinayagam et al. 2011) that was deposited in 
BioGRID (Biological General Repository for Interaction Databases). Therefore, we 
wanted to validate this interaction by co-immunoprecipitation (co-IP). A549 cells were 
transfected with HA-ERK3 and was then immunoprecipitated using ERK3 antibody 
followed by Western blotting. Indeed, SOCS3 co-immunoprecipitated with ERK3 (Fig 8 
a). In addition, a reverse co-IP experiment was performed using Flag Ab conjugated beads 
in A549 cells overexpressed with Flag-SOCS3. Again, we observed the co-
immunoprecipitation of ERK3 with SOCS3 (Fig 8 b). Taken together, these results clearly 
demonstrate that ERK3 and SOCS3 interact with each other. Next we wanted to investigate 
if ERK3 and SOCS3 proteins co-localize in cells. Both ERK3 and SOCS3 are shown to be  
found in the nucleus and cytoplasm (White et al. 2011; Lee et al. 2008). It was intriguing 
to see if there is a specific subcellular compartment where these two proteins could co-
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localize. For this A549 cells were co-transfected with pSG5-HA-ERK3 and pSG5-Flag-
SOCS3 and their cellular localization was visualized by immunofluorescence. As reported, 
both ERK3 and SOCS3 were localized in the nucleus and cytoplasm. Indeed, these two 
proteins show partial co-localization in those subcellular compartments. 
                                  a)                                                                 b) 
 
 






Figure 8: ERK3 interacts and colocalizes with SOCS3 
a) A549 cells were transfected with pSG5 HA-ERK3. 2 days post transfection, cells were 
harvested and lysed, and then cell lysates were incubated with ERK3 antibody or rabbit 
IgG for 1.5 hr. The immune complexes were then precipitated by incubating the Protein 
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A agarose beads for 1.5 hrs, followed by Western blotting analysis. b) A reverse co-
immunoprecipitation experiment was performed using Flag Ab-conjugated beads for 
cells transfected with Flag-SOCS3, followed by Western blotting. c) A549 cells were co-
transfected with pSG5-HA-ERK3 and pSG5-Flag-SOCS3 and then were analyzed by 
immunofluorescence. SOC3 was stained with Texas red, ERK3 was stained green with 
FITC and nucleus was stained blue with DAPI. The pictures were taken under 63X 
magnification. 
E. ERK3 interacts with SOCS3 with its C34 domain 
Now, that we have verified the interaction between ERK3 and SOCS3, we wanted to 
further reveal which fragment of ERK3 binds with SOCS3. For this purpose, we transiently 
co-overexpressed HA-SOCS3 and each of different flag-tagged ERK3 fragments (9 a) in 
293T cells. We then performed co-immunoprecipitation using HA beads to pull down 
SOCS3, followed by Western blotting (9b). As expected, we observed the interaction 
between SOCS3 and full length ERK3. Interestingly, among all three different ERK3 
fragments, only the C34 domain (aa 341- aa 481) showed a clear interaction with SOCS3. 
To confirm this, a reverse co-immunoprecipitation experiment was performed, in which 
the 293T cells were co-transfected with SOCS3 and different Flag-tagged ERK3 
fragments. ERK3 proteins were immunoprecipitated using Flag beads and results were 
analyzed by Western blotting. In agreement with the result in Fig 9b, SOCS3 co-
immunoprecipitated with full length ERK3 and C34 domain of ERK3 (9c). Taken together, 
these results suggest that C34 domain of ERK3 interacts with SOCS3. 
 










     
                                   c) 
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Figure 9: C34 domain of ERK3 interacts with SOCS3 
a) The schematic representation of full length and truncated fragments of ERK3 b) 293T 
cells were co-transfected with HA-SOCS3 and Flag tagged full length ERK3 or each of 
different truncated fragments. Two days post transfection, cells were lysed and the 
interaction of SOCS3 with different ERK3 fragments was analyzed by co-
immunoprecipitation using HA beads or Mouse IgG, followed by Western blotting. c) 
293T cells were again transfected with HA-SOCS3 and Flag tagged full length ERK3 or 
each of different truncated fragments. A reverse co-immunoprecipitation was performed 
using Flag beads to pull down the Flag-ERK3 complexes, followed by Western blotting.  
 
F. ERK3 facilitates the interaction of SOCS3 with JAK2 
 
SOCS3 inhibits the IL-6/STAT3 signaling by binding to JAK2 and inhibiting the 
phosphorylation of STAT3 (Yoshimura et al. 1995; Helman et al. 1998). Hence, we wanted 
to identify the effect of ERK3 on the interaction of SOCS3 with JAK2. To test this, HeLa 
cells were transiently co-transfected with Flag-SOCS3 plasmid and siControl or siERK3. 
24 hours later, the cells were serum starved for 24 hours followed by Vehicle or IL-6 
treatment. Co-immunoprecipitation was performed with flag beads for 3 hours followed by 
Western blotting analysis. As expected, ERK3 and JAK2 were coimmunoprecipitated with 
SOCS3. Interestingly, ERK3 knockdown lead to a decrease in the interaction of SOCS3 
and JAK2 (Fig 10), suggesting that ERK3 promotes the interaction of SOCS3 with JAK2, 
hence suppressing the STAT3 phosphorylation and activation. 
 




Figure 10: ERK3 promotes the interaction of SOCS3 with JAK2  
HeLa cells were transfected with Flag-SOCS3 and 30 nm of either siControl or siERK3. 
1-day post transfection, cells were serum starved for 24 hrs, followed by stimulation with 
40 ng/ml of IL-6 for 45 mins. Cells were harvested, and SOCS3 protein complex was 
immunoprecipitated by incubating cell lysates with Flag agarose beads followed by 
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IV. Discussion 
The family of Mitogen-activated protein kinases (MAPKs) comprises of 14 Ser/Thr kinases 
that are further classified into conventional MAPK and atypical MAPK based on their 
signaling profile and phosphorylation consensus (Coulombe and Meloche 2007). The 
conventional MAPKs such as ERK1/2, JNKs, p38 isoforms have a canonical Thr-XAA-
Tyr (TXY) phosphorylating activation motif. These proteins have been extensively studied 
and well characterized. Atypical MAPK such as ERK3 harbors a Ser-Glu-Gly (SEG) 
activation motif in its kinase domain. Although ERK3 was discovered almost at the same 
time as ERK1/2, little is known regarding its biochemical and physiological functions. 
 
Nonetheless, there have been some reports showing the importance of ERK3 in thymocyte 
activation and survival (Marquis et al. 2014), neuronal morphogenesis (Brand et al. 2012) 
and endothelial cell migration (W. Wang et al. 2014). In addition, various studies have 
reported important roles of ERK3 in several cancer types. It is upregulated in different 
human cancers, including non-small cell lung cancer (W. et al. 2012), gastric cancer (Liang 
et al. 2005) and oral squamous cancer (Rai, Mahale, and Saranath 2004). In line with its 
upregulation in these cancers, ERK3 promotes migration and invasion in lung cancer (W. 
et al. 2012), breast cancer (Al-Mahdi et al. 2015), head and neck cancer (Elkhadragy et al. 
2017). On the other hand, ERK3 plays inhibitory roles in some other cancers. ERK3 was 
shown to inhibit cell proliferation and tumor growth in intrahepatic cholangiocarcinoma 
(Ling et al. 2017) and hepatocarcinoma (Xiang, Wang, and Xiang 2014). ERK3 also 
suppresses the cell growth and migration/invasion of melanoma cells. Moreover, lower 
ERK3 expression in melanoma patients indicates poor prognosis of the disease (Hoeflich 
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et al. 2006; Chen et al. 2019). As a protein kinase, ERK3 has been shown to phosphorylate 
several substrates, including MK5 (Seternes et al. 2004; Schumacher et al. 2004), SRC-3 
(W. et al. 2012; Elkhadragy et al. 2018) and TDP2 ( Bian et al. 2016). 
 
In contrast, IL-6 is an extensively studied cytokine with a plethora of functions in various 
biological processes as well as pathological conditions. Being a cytokine, its major function 
lies within immune regulation where it plays both inflammatory and anti-inflammatory 
roles. Its functions range from B and T cell differentiation, hematopoiesis, acute 
inflammatory response to regulation of metabolic, regenerative and neural processes 
(Naka, Nishimoto, and Kishimoto 2002; Hunter and Jones 2015). In line with these critical 
functions, IL-6 signaling has been widely investigated and well-studied. This interest arises 
mostly due to the several health implications caused by the dysregulation of this pathway. 
Autoimmune diseases such as rheumatoid arthritis, diabetes type II, inflammatory bowel 
disease are some extensively studied diseases that are linked with irregulated IL-6 signaling 
(Luo and Zheng 2016; Hunter and Jones 2015). In addition, this pathway has a dynamic 
role in several cancer types. Frequently, dysregulation of IL-6 signaling is tied to cancer 
initiation and progression (Chonov et al. 2019; Zhao et al. 2018). In fact, several drugs 
targeting different proteins of this pathway have deemed successful in laboratories and are 
in the process of clinical trials (J.-F. Rossi et al. 2015; Trikha et al. 2003; Zhao et al. 2018). 
IL-6 signal is transduced via the JAK-STAT signaling pathway which is a highly regulated 
pathway. While several mechanisms for the negative regulation of this pathway have been 
discovered (P C Heinrich et al. 1998), SOCS3 is considered to be the most potent (Helman 
et al. 1998; Babon, Varghese, and Nicola 2014). 
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In this study, we first verified the negative effect of ERK3 on IL-6 target genes in A549 
and A375 cell lines. Irrespective of the cell lines and culture conditions, depletion of ERK3 
consistently led to the upregulation of IL-6 target genes IL6ST, IL10RB, STAT1. These 
results suggest that ERK3 negatively regulates the transcription of IL-6 response genes. 
We further found that ERK3 downregulates the phosphorylation of STAT3 at Y705 
residue. STAT3 is the major transcription factor activated by IL-6. In response to IL-6, 
STAT3 is recruited by IL6ST and subsequently phosphorylated by JAK2 at Y705 residue. 
The downstream effect of IL-6 is dictated by the phosphorylation of STAT3 at this residue 
since only Y705 phosphorylated STAT3 can dimerize to become an active transcription 
factor (Huang et al. 2014; P C Heinrich et al. 1998). Therefore, despite having several 
inhibitory mechanisms, most negative regulators of the IL-6 pathway act by regulating the 
phosphorylation of STAT3 at Y705 residue. 
 
SOCS3 is the most potent negative feedback regulator of the IL-6 signaling pathway 
(Babon, Varghese, and Nicola 2014a; Peter C Heinrich et al. 2003). Our study showed that 
ERK3 interacts with SOCS3 through its C34 domain.  Among all the MAP kinases, the 
C34 domain is unique to ERK3 and ERK4. Virtually nothing is known about the 
biochemical and physiological roles of C34 in ERK3 and ERK4 yet. Another unpublished 
study in our lab has shown the interaction of the C34 domain of ERK3 with diacylglycerol 
kinase zeta (DGKζ). Hence, we have revealed a novel function for the C34 domain, which 
is important for ERK3 (and possibly ERK4 as well) to interact with other proteins. This 
further opens new avenues to understand the biochemical and physiological roles of ERK3. 
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Next, we investigated how the ERK3-SOCS3 interaction is related to their inhibitory role 
in IL-6 signaling. SOCS3 suppresses the IL-6 signaling mainly by binding to the JH1 
domain of JAK2 via its KIR domain (Feng et al. 1997; Babon, Varghese, and Nicola 2014b) 
to prevent the Y705 phosphorylation and activation of STAT3. As we found that ERK3 
interacts with SOCS3 and downregulates STAT3 phosphorylation at Y705, we postulated 
that ERK3 may facilitate the interaction of SOCS3 with JAK2 to suppress IL-6 signaling. 
Indeed, ERK3 knockdown led to a decrease in the interaction between JAK2 and SOCS3. 
While we currently do not know the exact mechanism underlying this, we think ERK3, as 
a protein kinase, may phosphorylate SOCS3 and then alter its interaction with JAK2, 
thereby suppressing IL-6/STAT3 signaling (Fig 11). 
 
The importance of ERK3 in the downregulation of IL-6 signaling comes across clearly in 
IL-6 mediated migration of melanoma cells. IL-6/STAT3 signaling induces the migration 
of melanoma cells and is also upregulated in this type of skin cancer (Linnskog et al. 2014). 
On the contrary, a recent study from our lab showed that ERK3 decreases the migration of 
melanoma cells and is downregulated in melanoma (Chen et al. 2019). However, it is 
unclear how ERK3 decreases melanoma cell migration. The finding that ERK3 
downregulates IL-6/STAT3 signaling suggests that this may be the mechanism underlying 
the inhibitory role of ERK3 in melanoma cell migration. In support of this, ERK3 depletion 
greatly enhanced IL-6-induced A375 melanoma cell migration. This would also explain, 
at least partly, why the downregulation of ERK3 is associated with an increase in 
aggressiveness and higher tumor grade in melanoma. 
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Figure 11: A working model for ERK3 suppressing IL-6/STAT3 signaling pathway. 
We have identified a novel role of ERK3 in the negative regulation of IL-6/STAT3 
signaling. The C34 domain of ERK3 interacts with SOCS3, the negative feedback 
regulator of IL-6 signaling. This association further facilitates the interaction of SOCS3 
with JAK2, hence preventing the phosphorylation and subsequent activation of STAT3. 
This ultimately leads to the suppression of the transcription of IL-6 target genes. 
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